Therapeutic Development Services
Chronic myeloid leukemia (CML) is dangerous condition that affects human well-being. At Protheragen, we are working on the development of new therapeutic options, as well as attempting to create precise animal models for the preclinical research of prospective therapies for CML. With our know how, you can be sure that your studies will be given the most dependable and pertinent assistance making your drug development process much more efficient.
Chronic myeloid leukemia (CML) is uncommon type of blood cancer that occurs in the bone marrow, where there is an overproduction of aberrant white blood cells know as myeloid cells. These myeloid cells grow out of control and build up in the blood and bone marrow which interferes with normal blood cell formation. CML is aided by the presence of a Philadelphia chromosome which is a genetic defect due to a translocation of chromosomes 9 and 22. This alteration causes the BCR-ABL1 fusion protein and its consequent uncontrolled proliferation of leukemia cells.
Fig. 1 Progression of chronic myeloid leukemia. (Losson, Hélène, et al., 2020)
Chronic myeloid leukemia (CML) arises as a result of a genetic lesion that translocates between chromosomes 9 and 22 to form the Philadelphia chromosome. The translocation gives rise to BCR-ABL1 fusion gene, which produces a constitutively active tyrosine kinase protein. The BCR-ABL1 protein actively represses normal cellular communication, resulting in accumulation and growth of immature myeloid progenitors in the bone marrow and blood. The disease is further complexed over time with successive genetic alterations leading to more aggressive forms of CML.
Fig. 2 Schematic diagram of the pathogenesis of chronic myeloid leukemia (CML). (Hassan, Zair, et al., 2015)
The global chronic myeloid leukemia (CML) therapeutics market was valued at approximately USD 6.5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030. Despite the success of tyrosine kinase inhibitors (TKIs), challenges such as resistance, intolerance, and late disease progression highlight the need for continued innovation in CML therapeutic development.
Table. 1 Therapy development pipeline for chronic myeloid leukemia (CML).
| Drugs | Types | Targeted | Developmental Stage |
|---|---|---|---|
| Asciminib | STAMP inhibitor | BCR-ABL1 | Approved |
| Olverembatinib | Tyrosine kinase inhibitor | BCR-ABL1 (including T315I mutation) | Approved |
| Vodobatinib | Tyrosine kinase inhibitor | BCR-ABL1 (resistant mutations) | Phase II |
| PF-114 | Tyrosine kinase inhibitor | BCR-ABL1 (including T315I mutation) | Phase II |
| K0706 | Tyrosine kinase inhibitor | BCR-ABL1 | Phase II |
| TQ-B3101 | Tyrosine kinase inhibitor | BCR-ABL1, ALK, ROS1 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
At Protheragen, our unwavering commitment lies in delivering state-of-the-art diagnostic and therapeutic development services tailored specifically for chronic myeloid leukemia (CML), a challenging myeloproliferative disorder. Our expertise is centered around the development of innovative therapies spanning multiple molecular classes, meticulously studied in intricately crafted disease models during the preclinical phase.
Therapeutic Development Services
As a leading provider of therapeutic development services, Protheragen is focused on developing a variety of innovative therapies for chronic myeloid leukemia (CML) to address the complex challenges in this field.
Animal Model Development Services
Animal models are essential tools for understanding the biology of chronic myeloid leukemia (CML) and evaluating the efficacy and safety of potential therapies.
Protheragen is steadfastly dedicated to meticulously validating and optimizing therapies for chronic myeloid leukemia (CML) through a thorough series of pharmacodynamic, pharmacokinetic, and toxicology studies. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)